Prediabetic State
2
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Novartisvildagliptin
BayerDapagliflozin
LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes
Clinical Trials (3)
Total enrollment: 366 patients across 3 trials
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
Start: Oct 2005Est. completion: Jul 2006171 patients
Phase 3Completed
The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
Start: Feb 2016Est. completion: Jan 2019120 patients
Phase 2Completed
NCT06195566LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes
Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes
Start: Jan 2024Est. completion: Mar 202575 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
5 companies competing in this space